trifluoperazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2740 117-89-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • trifluoperazine
  • trifluoperazin
  • trifluoromethylperazine
  • trifluoroperazine
  • trifluperazine
  • triflurin
  • triperazine
  • trifluoperazine hydrochloride
  • trifluoperazine dihydrochloride
  • trifluoperazine HCl
  • flupazine
A phenothiazine with actions similar to CHLORPROMAZINE. It is used as an antipsychotic and an antiemetic.
  • Molecular weight: 407.50
  • Formula: C21H24F3N3S
  • CLOGP: 4.89
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 9.72
  • ALOGS: -4.67
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O
8 mg P
20 mg R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Benet LZ, Broccatelli F, Oprea TI

Approvals:

DateAgencyCompanyOrphan
April 16, 1959 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 70.29 54.11 24 395 59822 50544883

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Therapeutic product effect variable 349.85 202.69 61 1113 1816 29571537
Antipsychotic drug level below therapeutic 346.78 202.69 61 1113 1913 29571440
Disinhibition 329.84 202.69 61 1113 2546 29570807
Obsessive-compulsive disorder 319.21 202.69 65 1109 4511 29568842
Euphoric mood 298.20 202.69 62 1112 4763 29568590
Increased appetite 278.48 202.69 61 1113 6003 29567350
Akathisia 272.04 202.69 61 1113 6681 29566672

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Antipsychotic drug level below therapeutic 90.95 52.14 15 834 970 64496913
Therapeutic product effect variable 83.27 52.14 15 834 1629 64496254
Suicide attempt 79.02 52.14 31 818 70976 64426907
Disinhibition 78.62 52.14 15 834 2228 64495655
Euphoric mood 67.71 52.14 16 833 6575 64491308
Obsessive-compulsive disorder 67.19 52.14 15 834 4803 64493080
Blepharospasm 60.97 52.14 13 836 3362 64494521
Dyslipidaemia 57.47 52.14 15 834 9227 64488656
Increased appetite 56.08 52.14 15 834 10131 64487752
Akathisia 54.21 52.14 15 834 11495 64486388

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AB06 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Phenothiazines with piperazine structure
FDA CS M0016525 Phenothiazines
MeSH PA D000932 Antiemetics
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
FDA EPC N0000175746 Phenothiazine
CHEBI has role CHEBI:37930 phenothiazine antipsychotic drugs
CHEBI has role CHEBI:48561 dopaminergic antagonists
CHEBI has role CHEBI:50919 antiemetico
CHEBI has role CHEBI:77402 EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitors
CHEBI has role CHEBI:86385 Delta(7)-cholestenol Delta(7)-Delta(8)-isomerase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Anxiety indication 48694002
Schizophrenia indication 58214004 DOID:5419
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Cirrhosis of liver contraindication 19943007 DOID:5082
Glaucoma contraindication 23986001 DOID:1686
Orthostatic hypotension contraindication 28651003
Retinal disorder contraindication 29555009 DOID:5679
Alcoholic liver damage contraindication 41309000
Low blood pressure contraindication 45007003
Chronic hepatitis contraindication 76783007 DOID:2237
Epilepsy contraindication 84757009 DOID:1826
Tardive dyskinesia contraindication 102449007
Diminished sweating contraindication 111980002
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Carcinoma of female breast contraindication 447782002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.74 Basic
pKa2 4.74 Basic
pKa3 2.72 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.84 PDSP CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.19 PDSP
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.82 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 5.29 DRUG MATRIX
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Enzyme Ki 8.10 CHEMBL
Multidrug resistance protein 1 Transporter Ki 5.19 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 6.02 PDSP
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 7.90 IUPHAR
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 6.40 IUPHAR
5-hydroxytryptamine receptor 6 GPCR Ki 6.85 PDSP
Alpha-1A adrenergic receptor GPCR Ki 7.62 PDSP
Alpha-2B adrenergic receptor GPCR Ki 6.79 PDSP
D(3) dopamine receptor GPCR ANTAGONIST Ki 9.25 PDSP
Histamine H1 receptor GPCR ANTAGONIST Ki 7.20 IUPHAR
Muscarinic acetylcholine receptor M3 GPCR Ki 6 PDSP
Alpha-2C adrenergic receptor GPCR Ki 6.41 PDSP
D(4) dopamine receptor GPCR ANTAGONIST Ki 7.38 PDSP
Calmodulin Cytosolic other Kd 6 CHEMBL
DNA-dependent protein kinase catalytic subunit Kinase IC50 4 CHEMBL
Emopamil-binding protein-like Enzyme Ki 8.41 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.30 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 6.54 PDSP
Trypanothione reductase Enzyme Ki 4.64 CHEMBL
D(2) dopamine receptor GPCR Kd 9.27 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 6.39 CHEMBL
NS3 Enzyme IC50 6.15 CHEMBL
Beta-glucuronidase Enzyme IC50 5.11 CHEMBL
Lysozyme C-1 Enzyme IC50 5.05 CHEMBL
C-8 sterol isomerase Enzyme Ki 6.30 CHEMBL
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 5.85 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 7.53 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Kd 8.98 CHEMBL
Calmodulin Cytosolic other Kd 5.47 CHEMBL
Genome polyprotein Unclassified IC50 6.16 CHEMBL
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Enzyme IC50 4.35 CHEMBL

External reference:

IDSource
4019957 VUID
N0000148042 NUI
D00799 KEGG_DRUG
440-17-5 SECONDARY_CAS_RN
4018843 VANDF
4019957 VANDF
C0040979 UMLSCUI
CHEBI:45951 CHEBI
CHEMBL422 ChEMBL_ID
CHEMBL1257040 ChEMBL_ID
CHEMBL1710 ChEMBL_ID
D014268 MESH_DESCRIPTOR_UI
DB00831 DRUGBANK_ID
5566 PUBCHEM_CID
214 IUPHAR_LIGAND_ID
718 INN_ID
214IZI85K3 UNII
10800 RXNORM
2926 MMSL
5625 MMSL
d00890 MMSL
001481 NDDF
004590 NDDF
373524005 SNOMEDCT_US
50754002 SNOMEDCT_US
71699007 SNOMEDCT_US
TFP PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-2401 TABLET, FILM COATED 1 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-2402 TABLET, FILM COATED 2 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-2405 TABLET, FILM COATED 5 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-2410 TABLET, FILM COATED 10 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-8028 TABLET, FILM COATED 1 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-8028 TABLET, FILM COATED 1 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-8032 TABLET, FILM COATED 2 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-8032 TABLET, FILM COATED 2 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-8034 TABLET, FILM COATED 5 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-8034 TABLET, FILM COATED 5 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-8036 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-8036 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0494 TABLET, FILM COATED 1 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0495 TABLET, FILM COATED 2 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0496 TABLET, FILM COATED 5 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0497 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
TRIFLUOPERAZINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-305 TABLET, FILM COATED 2 mg ORAL ANDA 11 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51079-572 TABLET, FILM COATED 1 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51079-573 TABLET, FILM COATED 2 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51079-574 TABLET, FILM COATED 5 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51079-575 TABLET, FILM COATED 10 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53808-0629 TABLET, FILM COATED 2 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53808-0819 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-1960 TABLET, FILM COATED 10 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-2095 TABLET, FILM COATED 2 mg ORAL ANDA 16 sections
Trifluoperazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-2106 TABLET, FILM COATED 5 mg ORAL ANDA 16 sections